1. Introduction {#sec1}
===============

The acquired immunodeficiency syndrome (AIDS) was first identified in the early 1980s. At that time, 5-year survival rate was 3.4%, and patients faced a median survival of 12.5 months [@bib1]. AIDS has since exploded into one of the worst epidemics of recorded history. In the last 40 years, world-wide prevalence has exceeded 35 million, more than half of which are women and children, with over 2 million new cases emerging each year. Insights into the pathogenesis of AIDS as an infection has led to the development of both public health preventive measures and long-term medical therapies. The underlying cause of AIDS is the RNA retrovirus human immunodeficiency virus (HIV), which targets CD4+ T cells and macrophages [@bib2]. HIV integrates into the human genome, creating a persistent infection that requires life-long medical management [@bib3].

The advent of antiretroviral therapy (ART) has significantly decreased mortality in HIV-infected patients [@bib4], [@bib5]. However, long-term administration of ART medications is associated with a disproportionate rise in non-AIDS-related mortality. Prolonged ART does not restore proper immune function, and patients often exhibit premature immunological aging, persistent immune hyper-activation, and chronic inflammation [@bib6]. This is particularly troublesome given the decreased metabolic control in the HIV-1 patient population [@bib7] are co-morbidities, including cardiovascular diseases [@bib8], obesity [@bib9], non-alcoholic fatty liver disease (NAFLD), and type-2 diabetes (T2D) [@bib10], [@bib11]. Likewise, insulin resistance is observed in 35--63% of patients receiving ART, which greatly exceeds its prevalence in uninfected control populations [@bib12], [@bib13], [@bib14].

There is growing interest in understanding metabolic syndrome in HIV-infected adults [@bib15], yet the molecular mechanisms underlying metabolic syndrome in the context of HIV-1 infection under ART remain poorly understood. Thus, a deeper understanding of the complex interplay of genetics, immune responses, and therapeutic factors is needed to successfully develop clinical strategies against metabolic syndrome in HIV-1 patients.

Data herein illustrate that ART worsens HFD-induced metabolic derangements and exaggerates diet-induced adiposity. Combined transcriptomic and kinomic analyses of adipose tissue identified a diet-drug synergism that augments pro-inflammatory signaling within adipose tissue consistent with macrophage infiltration. These observations therefore support ongoing efforts to identify both novel therapeutic targets and modifiable clinical risks to improve the health and wellness of HIV-infected individuals.

2. Research design and methods {#sec2}
==============================

2.1. Animal model {#sec2.1}
-----------------

A cohort of 6-week-old, C57Bl/6J mice were obtained from the Jackson Laboratory. Mice were maintained on standard chow (4.7 kcal%, \#7917, Envigo, Indianapolis, IN) until 8 weeks of age, then given *ad libitum* access to standard chow or high fat diet (HFD, 58.0 kcal% fat, \#D12331 Research Diets, New Brunswick, NJ) for 12 weeks. Mice were group-housed (5/cage) on a 12:12-h light--dark cycle at 25 ± 1 °C and constant humidity with free access to food and water except as noted. Antiretroviral Therapy (ART/Atripla; Efavirenz, Emtricidabine, and Tenofovir disoproxil fumarate) was administered mixed within the diet such that dietary intake supplied ART doses equivalent to that of HIV patients (1100 mg/d or 14.67 mg/kg/d). All studies were approved by and performed according to the guidelines of the University of Alabama at Birmingham Institutional Animal Care and Use Committee.

2.2. Energy balance and body composition {#sec2.2}
----------------------------------------

Food intake and body weight were measured weekly. Body composition was assessed via non-invasive nuclear magnetic resonance spectroscopy (EchoMRI; Echo Medical Systems, Houston, TX) at the UAB Nutrition Obesity Research Center Small Animal Phenotyping Core.

2.3. Glucose and insulin tolerance tests {#sec2.3}
----------------------------------------

Glucose and insulin tolerance tests (GTT, ITT) performed by intraperitoneal (i.p.) injection of glucose (1.5 (chow-fed) or 2 g/kg (HF-fed), 20% wt/vol [d]{.smallcaps}-glucose \[Sigma\] in 0.9% wt/vol saline) or insulin (0.75 unit/kg in 0.9% wt/vol saline) to 6-hour fasted mice. Blood glucose was determined using TheraSense Freestyle Glucometer.

2.4. Tissue isolation {#sec2.4}
---------------------

Following 12 weeks of diet/ART administration, mice were fasted for 2 h (starting at 0800). Mice were briefly sedated with pentobarbital prior to decapitation. Trunk blood was collected, and epididymal white adipose tissues (eWAT) were harvested and stored at −80 °C until analysis. A portion of the eWAT was processed for adipose tissue macrophage isolation as described below.

2.5. Adipose-infiltrating macrophage isolation {#sec2.5}
----------------------------------------------

eWat tissue was minced, homogenized, and placed on a 40 μM strainer to obtain a single-cell suspension. Adipose macrophages were isolated by positive selection using biotinylated anti-F4/80 (eBioscience), streptavidin-conjugated magnetic beads (Miltenyi Biotec), and a LS magnetic column (Miltenyi Biotec) according to the manufacturer\'s protocol. Column-bound cells were then washed, counted, and frozen as a cell pellet for kinomic analysis.

2.6. Kinomic analysis {#sec2.6}
---------------------

The isoMultiplex *In Vitro* Kinase Assay platform uses a high-throughput peptide microarray system to analyze 144 tyrosine phosphorylatable peptides and 144 serine/threonine phosphorylatable peptides that have been imprinted and immobilized in a 3-D format to examine kinase activity of tissue lysate. Protein lysate of eWAT-isolated macrophages were analyzed as previously described [@bib16], [@bib17]. Briefly, isolated macrophage lysate was pooled yielding 3 pooled samples for each group to supply sufficient protein. Lysates were quantified and normalized using a dual standard BCA assay and dsDNA concentration then loaded at protein equivalents of 15 μg/well (Protein Tyrosine Kinase, PTK) or 2 μg/well (Serine/Threonine Kinase, STK) onto the PamChips for analysis using the PamStation12 instrument and software (Bionavigator software version 5.1, PamGene International, \'s-Hertogenbosch, The Netherlands). Raw fluorescence images were imported to BioNavigator for quantitative analysis. The first step in quantification required background normalization, allowing for fluorescence quantification at 10, 20, 50, 100, and 200 ms exposure. A slope-exposure value was then Log~2~-transformed for differential quantitation. To generate upstream kinase predictions, a *post hoc* unpaired t-test was then completed using Log~2~-transformed relative intensities via Kinexus Phosphonet ([www.phosphonet.ca](http://www.phosphonet.ca){#interref0010}), from which a "Normalized Kinase Statistic" was generated to rank and score putative kinase activity. Lastly, a Specificity Score was also computed to estimate the uniqueness of an identified kinase from associated phosphopeptides.

2.7. RNA sequencing analysis {#sec2.7}
----------------------------

Sequencing data have been deposited within the Gene Expression Omnibus repository (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110035>). Tissue RNA was isolated using the RNeasy Lipid Mini-Kit according to the manufacturer\'s instructions (Qiagen, Valencia, CA). High-throughput RNA sequencing was performed at the Heflin Genomics Core at the University of Alabama at Birmingham. Alignment of reads to the mm10 genome was accomplished using STAR [@bib18], raw counts generated using Samtools [@bib19], and differential gene expression performed using DESeq2 [@bib20] (1.18.1) within the R (3.4.2) statistical computing environment. Due to the sample size (*n* = 2), dispersion estimates were first determined via maximum likelihood, assuming that genes of similar average expression strength possess similar dispersion, as previously described [@bib20]. Gene-wise dispersion estimates were then shrunken according to the empirical Bayes approach, providing normalized count data for genes proportional to both the dispersion and sample size. Differential expression was determined from normalized read counts via log~2~ (fold-change) using the Wald test followed by Bonferroni-adjusted *P*-value (i.e. *Q*-value) for each aligned and annotated gene. Statistical significance was assessed via unpaired two-tailed Bonferroni-adjusted *P*-value (*Q*-value) \< 0.05. Differentially expressed genes (DEGs) were assumed biologically significant when \|Log~2~FoldChange\| \> 1 with normalized count sum \> 1.

2.8. Data visualization {#sec2.8}
-----------------------

Functional and network GSEA, along with curated literature-supported candidate upstream regulators, were performed using QIAGEN\'s Ingenuity Pathway Analysis (IPA^®^, QIAGEN Redwood City, [www.qiagen/ingenuity](http://www.qiagen/ingenuity){#interref0015}) on RNA sequencing datasets (Fold-Change \> 2, *P* \< 0.05, FPKM \> 2). Within this software, pathway analysis was done both on the individual datasets and as a combined 'comparison' analysis to determine overlapping enriched pathways. Heat map generation was performed using *pheatmap* package (1.0.8) within R, and VennPlex [@bib21] was used to create the Venn diagrams and determine overlapping genes. CIBERSORT was utilized to assess for transcriptional enrichment of immunologic cell types [@bib22].

2.9. Quantitative real-time PCR {#sec2.9}
-------------------------------

RNA was isolated as described above. cDNA was synthesized by reverse transcription PCR using SuperScript III, DNase treatment and anti-RNase treatment (Invitrogen, Carlsbad, CA). Single gene qPCR was performed as previously described [@bib23]. Data were normalized to housekeeping gene cyclophilin (*Ppia*), a complete list of primers and targets is provided in [Supplementary Table S1](#appsec2){ref-type="sec"}.

2.10. Statistics {#sec2.10}
----------------

All data are represented as mean ± standard deviation unless otherwise indicated. Glucose disappearance rate (k~g~) defined as (Δ blood glucose/minute). Statistical significance was determined using unpaired Student\'s *t*-tests or, where appropriate, one- and two-way analysis of variance (ANOVA) with multiple comparisons Tukey and Sidak post-test, respectively. Statistical analyses and data visualization were completed using GraphPad Prism version 7.0 for Macintosh (GraphPad Software, San Diego, CA) and R software, version 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was assigned when *P* \< 0.05 unless otherwise specified.

3. Results {#sec3}
==========

3.1. ART exacerbates diet-induced obesity {#sec3.1}
-----------------------------------------

Increased rates of obesity, T2D, and cardiovascular disease observed in ART-treated individuals suggest that ART may induce metabolic dysregulation. However, any changes in these individuals will be impossible to segregate from the effects of HIV-infection prior to treatment. Thus, we set out to assess the effects of ART on energy balance and glucose metabolism in a rodent model of diet-induced obesity (DIO). Eight-week old C57Bl/6J mice were assigned to groups matched for body weight and fat mass then provided *ad libitum* access to high-fat diet (HFD) or standard chow diet (SD), with or without ART. Mice maintained on SD displayed a slight decrease in % body weight gain in the presence of ART ([Figure 1](#fig1){ref-type="fig"}A, C; time--drug interaction, *P* = 0.003) as well as a trend (*P* = 0.058) for decreased body weight gain ([Figure 1](#fig1){ref-type="fig"}E). Conversely, and consistent with clinical observations, DIO in HFD-fed mice was exaggerated in the presence of ART ([Figure 1](#fig1){ref-type="fig"}B, D; time--drug interaction, *P* \< 0.0001) and was associated with a 29.5% increase in total body weight gain relative to the BW change in HFD-VEH ([Figure 1](#fig1){ref-type="fig"}F).Figure 1Effect of HFD and ART on Body Weight. Body weight was measured weekly in mice fed (A) normal chow or (B) high-fat diet (HFD) to examine differences in ART- versus vehicle-treated (VEH) mice (*n* = 10). Change in body weight relative to weight at t = 0 for (C) normal chow-fed or (D) HFD-fed mice. Change in body weight after the 80-day treatment period for (E) normal chow-fed and (F) HFD-fed mice, relative to starting body weight. All statistical comparisons were using 2-way ANOVA, reporting group mean (±S.E.). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.Figure 1

In chow-fed mice, ART reduction in body weight was associated with normal accumulation of fat mass ([Figure 2](#fig2){ref-type="fig"}A, B) and a slight reduction in lean mass accumulation ([Figure 2](#fig2){ref-type="fig"}C, D). HFD-fed mice on ART displayed a greater final ([Figure 2](#fig2){ref-type="fig"}E) and change in fat mass over the 12-week study ([Figure 2](#fig2){ref-type="fig"}F) that was associated with increased lean mass accrual ([Figure 2](#fig2){ref-type="fig"}G, H). In HFD-fed mice, ART was associated with increased food intake throughout the study ([Supplementary Figure S1A](#appsec2){ref-type="sec"}) and an overall increase in cumulative and total food intake as compared to vehicle controls ([Supplementary Figures S1B, C](#appsec2){ref-type="sec"}).Figure 2Effect of HFD and ART on Body Composition. Body composition was measured in mice given standard chow diet with or without ART, with (A) fat mass (grams) before and after 80-day experiment, (B) change in fat mass from the duration of the experiment, (C) lean mass, and (D) change in lean mass throughout the experiment (*n* = 10). Body composition was measured in mice given high-fat diet with or without ART, with (E) fat mass (grams) before and after 80-day experiment, (F) change in fat mass from the duration of the experiment, (G) lean mass, and (H) change in lean mass throughout the experiment. All statistical comparisons were using 2-way ANOVA, reporting group mean (±S.E.). \**P* \< 0.05, \*\**P* \< 0.01.Figure 2

3.2. ART worsens diet-induced glucose dysregulation {#sec3.2}
---------------------------------------------------

Increased adiposity and glucose homeostasis are often inversely associated [@bib24]. We therefore assessed glucose tolerance after 8 weeks of ART treatment to determine its effect on glucose regulation. Similar to its effects on obesity, ART stimulated a mild increase in the glucose tolerance of SD-fed mice as determined by reduced glucose excursion and area under the curve (AUC) analysis ([Figure 3](#fig3){ref-type="fig"}A). Conversely, HFD-ART mice displayed greater intolerance as determined by glucose excursion and AUC analysis as compared to the already glucose intolerant vehicle-HF-fed mice ([Figure 3](#fig3){ref-type="fig"}B). Furthermore, while SD-ART mice displayed a trend (*P* = 0.054) for increased insulin action as determined by glucose excursion and rate of disappearance (k~g45~; [Figure 3](#fig3){ref-type="fig"}C) during i.p. ITT. In contrast, HFD-fed mice treated with ART exhibited a trend of decreased insulin action as compared to HFD-VEH mice ([Figure 3](#fig3){ref-type="fig"}D). Although fasting blood glucose of ART-treated mice was not different from vehicle-controls in either diet ([Figure 3](#fig3){ref-type="fig"}E), ART-treated, HFD-fed mice displayed exaggerated hyperinsulinemia as compared to the already hyperinsulinemic HFD-fed controls ([Figure 3](#fig3){ref-type="fig"}F). This hyperinsulinemia also drove an elevation in insulin resistance as determined by HOMA-IR ([Figure 3](#fig3){ref-type="fig"}G). Altogether these data suggest that ART synergistically disrupts glucose metabolism and energy balance in a diet-dependent manner.Figure 3Effect of HFD and ART on Glucose Homeostasis. Intraperitoneal (i.p.) glucose tolerance testing (GTT) was performed on mice given (A) standard chow diet with/without ART (*n* = 8), or (B) high-fat diet with/without ART (*n* = 10). I.p. insulin tolerance testing (ITT) was performed on mice given (C) standard chow diet with/without ART (*n* = 8), or (D) high-fat diet with/without ART (*n* = 10). (E) Four-hour fasting blood glucose measurements were taken across all 4 experimental groups at 12-weeks. (F) ELISA-based methods were used to measure circulating insulin levels in all 4 groups at 12-week time point. (G) Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated for all 4 experimental groups at the 12-week time-point using the equation HOMA-IR = (\[Glucose\] × \[Insulin\])/405. All statistical comparisons were using 2-way ANOVA, reporting group mean (±S.E.). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.Figure 3

3.3. ART potentiates diet-induced inflammatory transcriptomic changes in adipose tissue {#sec3.3}
---------------------------------------------------------------------------------------

To determine whether shifts in the transcriptional landscape underlie the physiologic decrements observed in HFD-ART feeding, we performed RNA sequencing of epididymal white adipose tissue (eWAT). Hierarchical clustering and heatmap visualization of the ART vs. VEH revealed a modest segregation between HFD and SD mice within both ART- and VEH-treated groups (*P* \< 0.05, [Figure 4](#fig4){ref-type="fig"}A and [Supplementary Table S2](#appsec2){ref-type="sec"}). Examination of the overlapping differentially expressed genes (DEGs) by ART in the SD- and HFD-fed mice (i.e. ART specific effects) elucidated only 199 genes of the total 1,089 DEGs ([Figure 4](#fig4){ref-type="fig"}B and [Supplementary Tables S3--S5](#appsec2){ref-type="sec"}). To determine whether HFD-ART synergy adversely affects the metabolic transcriptional programming of eWAT, differentially-expressed genes were examined according to known association with GO-term pathway "Diabetes Mellitus Signaling in Adipocytes", identifying the following 9 genes ([Figure 4](#fig4){ref-type="fig"}C): *Adipoq*, *Ikbke*, *Fgfr2*, *Irs1*, *Irs2*, *Pik3cg*, *Pik3r5*, *Prkaa2*, and *Prkcd*. Furthermore, the most robustly differentially expressed gene by Log~2~(Fold-Change) in HFD-ART vs. HFD-VEH was G-protein coupled receptor 50 (*Gpr50*) (35.5-fold, *Q* \< 0.001), induction of which has been previously implicated in the dysregulation of glucose homeostasis ([Figure 4](#fig4){ref-type="fig"}D) [@bib25].Figure 4Dietary Differences in the Transcriptional Effect of ART in eWAT. (A) Hierarchical clustering and heatmap visualization of differential gene expression (*n* = 2) based on ART vs. VEH comparison (*P* \< 0.05); complete gene list and fold-changes listed in [Supplementary Table S2](#appsec2){ref-type="sec"}. (B) Venn Diagram of differentially-expressed genes by ART vs. Vehicle for the SD- or HFD-fed mice; complete gene list and fold-changes per sector listed in [Supplementary Tables S3--S5](#appsec2){ref-type="sec"}. (C) Gene Set Enrichment Analysis was performed on the differentially expressed genes (DEGs) by ART vs. Vehicle comparison only in HFD (*P* \< 0.05) to determine differential expression of HFD-ART vs. HFD-VEH (*P* \< 0.05) was used to populate GO-Term Pathway "Diabetes Mellitus Signaling in Adipocytes". (D) Most robustly differentially-expressed gene and \*validation using qPCR (*n* = 6). Top 10 GO Term Enriched Pathways to identify putative upstream regulators. \$ Q \< 0.05 for HFD-ART vs. HFD-VEH; Ψ Q \< 0.05 for HFD-ART vs. SD-VEH; \#Q \< 0.05 for HFD-VEH vs. SD-VEH.Figure 4

To examine gene networks likely responsible for the observed metabolic transcriptional reprogramming, GO Term (i.e. 'Canonical') pathway enrichment was used to rank regulatory pathways by both statistical significance and percent enrichment. This analysis uncovered pathways linked to macrophage-phagocytosis (phagocytosis in macrophages and phagosome formation), -activation/signaling (LXR/RXR activation, pattern recognition receptors, nitric oxide (NO) and reactive oxygen species (ROS) signaling in macrophages, IL-8 signaling, and GM-CSF signaling), and cytoskeleton rearrangement (actin cytoskeleton signaling) ([Figure 4](#fig4){ref-type="fig"}E).

Examining the genes responsible for enriching the top 5 pathways revealed a sub-group of genes that were assigned to many of the top pathways, most notably *Sema4d*, *Pgf*, *Plxnc1*, *Fes*, *Sdcbp*, and *Fgfr2*. Furthermore, the majority of genes responsible for driving pathway enrichment were increased in HFD-ART relative to HFD-VEH ([Figure 5](#fig5){ref-type="fig"}). Together, these observations provide evidence that an immunologic cell population shift could be driving the differential gene expression.Figure 5Hierarchical Pathway Enrichment Clustering. The genes responsible for populating the top 5 enriched pathways generated via Ingenuity Pathway Analysis (IPA) were clustered via Euclidean distance, with heatmap of Log~2~(Fold-Change). Differential gene expression was assessed via RNA sequencing analysis (*n* = 2) and was considered significant at the *P* \< 0.05 level for this visualization.Figure 5

3.4. ART-stimulated immune cell flux {#sec3.4}
------------------------------------

To determine which infiltrating immunologic cell types, if any, were likely responsible for the pathway enrichment, the RNA sequencing data were inspected further using CIBERSORT [@bib26], a supervised machine learning model for cellular deconvolution. We combined this model with a transcriptional signature matrix of isolated immune cell types as developed by Chen et al. [@bib27]. Unsupervised (unbiased) hierarchical clustering of the resulting enrichment matrix revealed that the effect of ART in SD-fed mice produced trivial effects on the immune signature, whereas diet appeared to drive sample clustering ([Figure 6](#fig6){ref-type="fig"}A). Nevertheless, it was evident that, among the HF-fed mice, a sub-clustering existed between ART- and VEH-treated mice. This analysis therefore shows a predictive model capable of distinguishing HFD-ART from HFD-VEH groups based solely on their immune signature.Figure 6Whole-Tissue eWAT from HFD-ART Mice Possess a Transcriptional Fingerprint Consistent with Macrophage Enrichment. The CIBERSORT algorithm developed by Newman et al. [@bib22] was used to estimate the proportional enrichment of sequenced isolated immune cells based on mRNA expression of whole-tissue eWAT (*n* = 2), using the signature expression matrix developed by Chen et al. [@bib27]. (A) Unsupervised hierarchical clustering via Ward\'s minimum least squared method was used to determine the cell-type signature among eWAT samples by both Diet and Treatment. (B) Enrichment (%) of whole-tissue sequencing of eWAT under dietary and treatment conditions by isolated sequenced immunologic cell types, based on Pearson\'s correlation. (C) Pathway analysis to identify the top 5 upstream regulators to explain differential gene expression. (D) Mean gene expression (±S.D.) of common gene markers of macrophage infiltration and activation as determined by RNA-sequencing analysis of whole-tissue eWAT.Figure 6

In order to determine the immune cell type(s) responsible for driving the group clustering, we then quantified the proportional enrichment of each isolated immune cell type ([Figure 6](#fig6){ref-type="fig"}B). This analysis elucidated an increased macrophage enrichment in HFD-VEH relative to SD-VEH mice ([Figure 6](#fig6){ref-type="fig"}B). Furthermore, while ART failed to increase macrophage signature in SD-fed mice, HFD-ART mice exhibited robustly increased macrophage expression beyond that of HF-feeding alone (Pearson\'s ρ = 0.70, *P* \< 0.01) ([Figure 6](#fig6){ref-type="fig"}B). This observation was consistent with the gene set enrichment analysis, suggesting that eWAT-infiltrating macrophages are at-least partially responsible for differential gene expression in the HFD-ART vs. VEH-HFD comparison.

We next looked to putative upstream regulators to determine whether known cytokines or signaling cascades could confirm the CIBERSORT-based immunologic enrichment analysis ([Figure 6](#fig6){ref-type="fig"}C). This analysis suggested activation and enrichment of established upstream regulators of M1 macrophage polarization (TNF-α, IL-6, and CSF2). Lastly, in order to authenticate this immunologic signature, we examined macrophage gene expression markers ([Figure 6](#fig6){ref-type="fig"}D), which exhibited an expression pattern that increased or trended upwards beyond that of HFD alone: CD68 (*Cd68*, 2.8-fold, *P* = 5.4 × 10^−5^), CD11b (*Itgam*, 1.5-fold, *P* = 0.001), CD11c (*Itgax*, 1.7-fold, *P* = 0.054), F4/80 (*Emr1*, 2.1-fold, *P* = 0.001), and CXCR4 (Cxcr4, 1.47-fold, *P* = 0.035). Gene markers of B lymphocytes (*Cd19*, *Ms4a1*, *Ptprc*, *Cd22*), T lymphocytes (*Cd3d*, *Cd3e*, *Cd3g*, *Cd4*, *Cd8a*), and neutrophils (Mpo, Ly6g5b, Ly6g6c and Ly6g6d) were not significantly changed in HFD-ART relative to HFD-VEH ([Supplementary Figure S2](#appsec2){ref-type="sec"}). Altogether, these data suggest that the inflammatory eWAT transcriptional signature is likely due to the increased presence of adipocyte-infiltrating macrophages in the HFD-ART combination beyond that of HFD alone.

3.5. Kinomic analysis of isolated eWAT macrophages {#sec3.5}
--------------------------------------------------

Kinomic analysis of the eWAT infiltrating macrophages was conducted to predict upstream kinase activity and to identify putative intracellular regulators underlying the inflammatory signals and metabolic derangements. Interrogation of protein tyrosine kinase (PTK) activity suggested suppression of BMX non-receptor tyrosine kinase (encoded by *Bmx*), insulin receptor (encoded by *Insr*), and protein kinase C delta (encoded by *Prkcd*) in ART-treated HF-fed mice as compared to vehicle, HFD-fed controls ([Figure 7](#fig7){ref-type="fig"}A). This predicted kinase activity is consistent with the whole-eWAT transcriptional metabolic pattern noted previously. Most notably, however, was that Serine/Threonine Kinase analysis revealed increased activity of p38^*MAPK*^ and HIPK1([Figure 7](#fig7){ref-type="fig"}B), both of which are central to macrophage M1 polarization and activation [@bib28], [@bib29]. Lastly, we used a combined analysis comparing kinomic and transcriptomic signatures to determine if p38^*MAPK*^ signaling was likely controlling and/or controlled by transcriptional changes ([Figure 7](#fig7){ref-type="fig"}C). We noted that, among the genes with known connection to p38^*MAPK*^ signaling, many are involved in both macrophage activation (*Tlr1*, *Cd14*, *Cxcr4*, *Ccr5*, etc.) and metabolic activity (*Ppara*, *Klf4*, *Klf15*, *Igf2*, *Adipoq*, etc.). HIPK1 was also examined for overlapping gene interactions but lacked comparable enrichment (data not shown). Altogether, these data suggest that ART exacerbates HFD-induced macrophage infiltration and activation via p38^*MAPK*^ activation.Figure 7Regulatory Upstream Kinase Activity in ART-Diet Interaction. Kinomics-based analysis of putative upstream (A) Protein Tyrosine Kinase (PTK) and (B) Serine/Threonine Kinase (STK) activity, with kinases ranked according to both specificity score and k-statistic (*n* = 3). (C) p38^*MAPK*^ nodal regulation via IPA^®^ curation of differentially-expressed genes in HFD-ART vs. HFD-VEH (*P* \< 0.05).Figure 7

4. Discussion {#sec4}
=============

Prior generations of protease inhibitors and thymidine-analogue nucleoside reverse-transcriptase inhibitors (NRTIs) were associated with lipodystrophy and impaired glucose uptake [@bib12], [@bib13], [@bib14]. Newer therapeutics with lower side-effect profiles such as Atripla, have replaced these earlier interventions and abrogated much of the lipodystrophy observed in this population. However, the use of these next generation ARTs is accompanied by obesity, NAFLD, and elevated T2D risk [@bib10], [@bib30], [@bib31]. Although clinically reported, the underlying mechanism(s) for these metabolic abnormalities remains unknown. In this study, we utilized a DIO rodent model (i.e. high fat fed C57Bl/6J mice) to investigate the physiology and molecular signals altered during ART treatment. The use of this model allows us to eliminate confounding factors associated with HIV infection to more specifically test the interaction of ART and diet. We identified transcriptional signatures of increased adipose tissue inflammation associated with exacerbated glucose intolerance and accelerated DIO in HFD-ART mice. We further investigated the kinomic regulation of adipose-resident macrophages and observed markers of inflammation and impaired insulin signaling following ART treatment.

We found that ART-induced fat mass accumulation and glycemic dysregulation surpasses HFD alone. Lean body mass also increased in HFD-ART beyond that of HFD alone, a finding that is particularly intriguing given the concomitant disruptions in glucose handling; increases in skeletal muscle would be expected to improve glucose tolerance even in the context of insulin insensitivity. Importantly, however, ART-impairment of glucose homeostasis and insulin resistance was restricted to HF-fed mice. This finding is consistent with the Veterans Aging Cohort Study, in which reverse transcriptase inhibitor-based HIV treatment profoundly increased the risk ratio of diabetes associated with increasing BMI [@bib32]. The ART treatment utilized in the current study is a combination of efavirenz, emtricidabine, and tenofovir disoproxil fumarate. Used by almost a third of HIV-patients taking ART, the combination of efavirenz, emtricidabine, and tenofovir disoproxil fumarate is a common first-line therapeutic, but the combinatorial effects of this treatment on metabolic dysregulation has not been characterized [@bib33]. Individually, efavirenz-based treatment is associated with a 21% insulin resistance prevalence, although this risk was reduced in patients treated with NRTIs rather than protease inhibitors [@bib34], suggesting that efavirenz *per se*, may not be the driving factor. Emtricidabine treatment has not been associated with insulin resistance and importantly, emtricidabine and tenofovir fail to impair insulin resistance in healthy individuals [@bib35]. Overall these reports, along with our current findings, suggest that a complex interaction between the combined components of ART treatment and HFD-feeding impairs regulation of energy balance and glucose metabolism. Recent findings suggest that ART-treated women display greater insulin sensitivity as compared to otherwise matched male patients, despite greater baseline risk factors [@bib36]. Of note, our studies were conducted in male mice and thus we were unable to assess sex-associated differences, but our future studies will address sex-dependent ART effects. Such studies may require the use of thermoneutral animal housing, as prior studies examining sexual dimorphisms in metabolic response emphasize its importance in experimental design [@bib37]. Importantly, our mouse model can be exploited, via depletion antibodies or genetic knockout strategies, to perform mechanistic studies to further examine the interplay of ART treatment and HFD on obesity and glucose metabolism in the absence of CD4 T cells, similar to patients with HIV.

Chronic, low-grade inflammatory hyper-activation has been established as a contributor to insulin resistance, obesity, and overall metabolic dysregulation [@bib38]. This complex and systemic response involves macrophage infiltration into adipose tissue as well as the inappropriate production of inflammatory cytokines and chemokines such as IL-6, IL-1β, CCL2, and TNF-α [@bib39]. In lean mice and humans, macrophages constitute around 5% of the cells in the adipose tissue, are dispersed throughout the tissue, and exhibit limited inflammatory properties [@bib40], [@bib41], [@bib42]. However, during obesity, ATMs increase 10-fold and make up 50% of all adipose tissue cells [@bib40]. Moreover, these ATMs surround dead adipocytes forming crown-like structures with a pro-inflammatory phenotype that is directly associated with insulin resistance [@bib41], [@bib42]. ATMs are recruited to the adipose tissue via chemokine signaling, induce transcriptional changes in insulin-dependent metabolic signaling, and contribute to obesity-associated T2D [@bib43]. Consistent with a causal role in the disease, systemic suppression of inflammation in T2D patients improves glycemic control [@bib44]. However, this system is poorly understood in the context of HIV-infected patients. In the current study, we found that, although ART alone was insufficient to induce transcriptomic changes consistent with macrophage infiltration and activation, it induced robust inflammatory changes consistent with macrophage infiltration and activation in HF-fed mice beyond that of HFD alone. This finding is especially germane to HIV serodiscordant couples where ART is utilized in uninfected individuals to prevent transmission [@bib45]. While examining this drug--diet interaction was warranted in the absence of HIV infection, future studies are needed to determine the effects of this diet-drug synergy within an immunocompromised host.

Macrophages display significant plasticity and in response to environmental triggers can polarize to two broad subtypes; "classical" M1 macrophages and "alternatively-activated" M2 macrophages [@bib46]. However, the M1 and M2 macrophage nomenclature has been refined to depict the cytokine or polarization condition to induce multiple phenotypes including M(IL-4), M(Ig), M(IL-10), M(IFN-γ), M(LPS), etc. [@bib47]. Partly due to their plastic nature and different models of obesity, classification of M1 and M2 macrophages as being pro-inflammatory and anti-inflammatory in adipose tissue is not rigid. As opposed to the production of pro- and anti-inflammatory cytokine synthesis, it has been proposed that the phenotype of ATMs should be characterized by changes in lipid metabolism since fatty acids are the main trigger for metabolic activation of ATMs [@bib48]. Our transcriptional data demonstrate an increase in pro-inflammatory macrophage infiltration in adipose tissue and display a M1-like phenotype as evidenced by the activation of the p38^*MAPK*^ pathway and an increased transcription of pro-inflammatory effector molecules including TNF-α, IL-8, NO, and ROS synthesis. However, there is evidence that M2-like macrophages in the adipose tissue of obese individuals can produce pro-inflammatory cytokines [@bib49]. These ATMs display a heterogeneous phenotype of both M1- and M2-type macrophage markers, but more importantly, are associated with insulin resistance [@bib50]. Thus, our future studies will involve additional characterization of macrophage phenotypes from C57BL/6 mice on a HFD-ART regimen and, importantly, to define their contribution to insulin resistance and obesity. Likewise, although current studies have focused on eWAT inflammation, it is likely that similar defects are occurring other metabolic tissues (i.e. other adipose depots, liver, hypothalamus, and skeletal muscle).

In our search for a candidate regulator of the differential effects of ART in a diet-dependent manner, we found the "melatonin-related" G-protein coupled receptor 50 (*Gpr50*) as most robustly induced by RNA-sequencing and qPCR. Despite its structural similarity with the melatonin receptor family, *Gpr50* does not bind to melatonin. Instead, it has been shown to regulate whole-body energy and temperature homeostasis via its actions in the hypothalamus. Likewise, *Gpr50*-deficient mice exhibit lower body mass on normal chow and are DIO resistant [@bib25]. Moreover, *Gpr50* regulates adaptive thermogenesis in response to leptin signaling [@bib51], and polymorphisms in this gene have also been associated with increased levels of circulating triglycerides and obesity [@bib52]. It is currently unknown if *Gpr50* regulates adipose-tissue macrophage infiltration or inflammation. However, our data support that ART-fed mice display enhanced eWAT *Gpr50* expression associated with metabolic dysfunction. Thus, our future analyses will determine if *Gpr50* is an effective molecular target. Importantly, we will determine if *Gpr50*-dependent signaling has a role in adipose-tissue inflammation under conditions of ART treatment and DIO in mouse models and in translational studies with patients with HIV that have metabolic syndrome.

While the current study is a necessary first step in identifying the interaction between ART and diet, additional studies are warranted to provide both mechanistic and contextual insight into the complexities of long-term HIV treatment. We observed that a high-calorie diet enriched in fat is required for ART-induced metabolic defects, it remains unknown whether it is the effect of specific nutrients, or total caloric excess via hyperphagia underlying these complication\'s. To test the latter, future studies will make use of the hyperphagic *ob/ob* mouse as well as energy-restricted pair-feeding of C57Bl/6J mice [@bib53]. Likewise, chronic ART-treatment of HIV-infected individuals is associated with marked changes in the gut flora [@bib54], a key regulator of metabolic homeostasis [@bib55] that could also be contributing to the observed effects. Lastly, studies should examine other tissues to characterize the system-wide metabolic responses regulated by other tissues, since adipose tissue is one of many metabolic organs.

Until more effective targeted therapies are developed to address ART-associated metabolic syndrome, food-intake modification via dietary counseling remains the most promising method of clinical intervention. The use of lipid-lowering drugs improves risk of metabolic complications, but their use in HIV patients is avoided due to the heightened toxicity risks in HIV patients and drug interactions with ART [@bib56]. Short-term dietary interventions to reduce fat intake have successfully attenuated the dyslipidemia associated with ART [@bib57], although metabolic sequelae have not yet been adequately studied. HIV-positive patients with lower socioeconomic status suffer from higher mortality rates, an observation that is particularly alarming considering the disproportionately high incidence of HIV seroconversion in this demographic [@bib58].

5. Conclusions {#sec5}
==============

Together, these analyses provide an extensive description of the functional metabolic and transcriptional changes induced during anti-retroviral therapy and high-fat feeding. Our studies demonstrate that ART synergizes with high-fat feeding to induce chronic inflammatory signaling. This escalation of diet-induced inflammation likely results from enhanced eWAT macrophage infiltration that contributes to metabolic syndrome. Therefore, while chronic ART treatment has dramatically extended lifespan for HIV-infected individuals, it is apparent that these therapeutics also alter susceptibility to diet-induced metabolic defects. Our observations identify several avenues for novel targeted therapy, but moreover we highlight the potential importance of dietary intervention as a clinical consideration to improve the life-long management of HIV-infected individuals.
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The following are the supplementary data related to this article:Supplementary Figure S1Effect of ART on Food Intake in HFD Fed Mice. (A) Average daily food intake, (B) Cumulative food intake, and (C) Total food intake (±SEM) measured as grams of HFD chow consumed per mouse per day (g/mouse/d), with statistical comparison made between HFD-ART and HFD-VEH groups. Statistical significance was made based on *P* \< 0.05 using 2-way ANOVA and Sidak\'s multiple comparisons test.Supplementary Figure S1Supplementary Figure S2Gene markers of Immunologic Cells. Differential gene expression (Mean ± S.D.) of immunologic markers for B lymphocytic, T lymphocytic, and neutrophilic infiltration and activation as determined by RNA-sequencing analysis of whole-tissue eWAT (*n* = 2). Differential expression was assessed using HFD-ART vs. HFD-VEH comparison at P \< 0.05 level.Supplementary Figure S2
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